NORTHERN TRUST CORP - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 1 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$12,000
-52.0%
49,1480.0%0.00%
Q2 2022$25,000
-95.1%
49,148
-80.4%
0.00%
Q1 2022$514,000
-53.9%
250,768
-6.2%
0.00%
Q4 2021$1,116,000
-54.1%
267,452
+2.4%
0.00%
Q3 2021$2,429,000
-41.5%
261,226
+13.3%
0.00%
-100.0%
Q2 2021$4,152,000230,5290.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q4 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 1,887,509$977,0001.71%
Naviter Wealth, LLC 1,572,803$814,0000.33%
ARMISTICE CAPITAL, LLC 4,342,561$2,248,0000.04%
INVERNESS COUNSEL LLC /NY/ 1,210,537$627,0000.04%
Ground Swell Capital, LLC 13,616$7,0000.01%
BALDWIN BROTHERS LLC/MA 40,604$21,0000.00%
Allegheny Financial Group LTD 11,595$6,0000.00%
Ergoteles LLC 145,500$75,0000.00%
Renaissance Technologies 1,215,800$629,0000.00%
Carmichael Hill & Associates, Inc. 1,500$1,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders